ADIPOQ/adiponectin Induces Cytotoxic Autophagy in Breast Cancer Cells Through STK11/LKB1-mediated Activation of the AMPK-ULK1 Axis
Overview
Authors
Affiliations
ADIPOQ/adiponectin, an adipocytokine secreted by adipocytes in the breast tumor microenvironment, negatively regulates cancer cell growth hence increased levels of ADIPOQ/adiponectin are associated with decreased breast cancer growth. However, its mechanisms of action remain largely elusive. We report that ADIPOQ/adiponectin induces a robust accumulation of autophagosomes, increases MAP1LC3B-II/LC3B-II and decreases SQSTM1/p62 in breast cancer cells. ADIPOQ/adiponectin-treated cells and xenografts exhibit increased expression of autophagy-related proteins. LysoTracker Red-staining and tandem-mCherry-GFP-LC3B assay show that fusion of autophagosomes and lysosomes is augmented upon ADIPOQ/adiponectin treatment. ADIPOQ/adiponectin significantly inhibits breast cancer growth and induces apoptosis both in vitro and in vivo, and these events are preceded by macroautophagy/autophagy, which is integral for ADIPOQ/adiponectin-mediated cell death. Accordingly, blunting autophagosome formation, blocking autophagosome-lysosome fusion or genetic-knockout of BECN1/Beclin1 and ATG7 effectively impedes ADIPOQ/adiponectin induced growth-inhibition and apoptosis-induction. Mechanistic studies show that ADIPOQ/adiponectin reduces intracellular ATP levels and increases PRKAA1 phosphorylation leading to ULK1 activation. AMPK-inhibition abrogates ADIPOQ/adiponectin-induced ULK1-activation, LC3B-turnover and SQSTM1/p62-degradation while AMPK-activation potentiates ADIPOQ/adiponectin's effects. Further, ADIPOQ/adiponectin-mediated AMPK-activation and autophagy-induction are regulated by upstream master-kinase STK11/LKB1, which is a key node in antitumor function of ADIPOQ/adiponectin as STK11/LKB1-knockout abrogates ADIPOQ/adiponectin-mediated inhibition of breast tumorigenesis and molecular analyses of tumors corroborate in vitro mechanistic findings. ADIPOQ/adiponectin increases the efficacy of chemotherapeutic agents. Notably, high expression of ADIPOQ receptor ADIPOR2, ADIPOQ/adiponectin and BECN1 significantly correlates with increased overall survival in chemotherapy-treated breast cancer patients. Collectively, these data uncover that ADIPOQ/adiponectin induces autophagic cell death in breast cancer and provide in vitro and in vivo evidence for the integral role of STK11/LKB1-AMPK-ULK1 axis in ADIPOQ/adiponectin-mediated cytotoxic autophagy.
The adipokines in oral cancer pathogenesis and its potential as a new therapeutic approach.
Wang X, Wang J, Zhao X, Zhang J, Zhang Y Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40056203 DOI: 10.1007/s00210-025-03939-w.
Rajabi S, Shakib H, Safari-Alighiarloo N, Maresca M, Hamzeloo-Moghadam M Iran J Basic Med Sci. 2024; 27(12):1475-1491.
PMID: 39539439 PMC: 11556757. DOI: 10.22038/ijbms.2024.79405.17201.
Asiri A, Al Qarni A, Bakillah A Diagnostics (Basel). 2024; 14(19).
PMID: 39410536 PMC: 11475808. DOI: 10.3390/diagnostics14192132.
Next-Cell Hypothesis: Mechanism of Obesity-Associated Carcinogenesis.
Engin A, Engin A Adv Exp Med Biol. 2024; 1460:727-766.
PMID: 39287871 DOI: 10.1007/978-3-031-63657-8_25.
Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects.
Cheng H, Su G, Wu Y, Chen G, Yu Z J Pharm Anal. 2024; 14(7):100920.
PMID: 39104866 PMC: 11298875. DOI: 10.1016/j.jpha.2023.12.010.